Cantor Fitzgerald maintained an Overweight rating on NewAmsterdam Pharma Company N.V. (NAMS) on February 19, 2026. The firm also reiterated a $49.00 price target in its note, as reported by market outlets. StreetInsider covered the update.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Australia’s court fined ANZ $165.5 million, raising governance concerns and impacting investor confidence. Explore the implications and stock market’s
Daisy Cooper proposes UK Treasury reform: scrap HM Treasury and create a Birmingham-based Department for Growth. What this Lib Dem economic plan could mean for UK markets.
Pre-market: HOT.SW stock at CHF311.00, up 112%; Meyka grade, fundamentals and model forecast for Hochtief AG on SIX
Discover how recent banking changes disrupt PF balance checks, affecting EPF accounts. Learn important deadlines and actions.
SIS.AX stock trades A$0.007 pre-market ahead of 29 Jan earnings; Meyka AI flags cash risk and projects A$0.010 monthly target
AVAX.SW stock falls to CHF1.83 pre-market on 20 Jan 2026; outlook, Meyka AI grade, and CHF3.72 forecast